CONFIDENTIAL TREATMENT INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • May 15th, 2014 • Arno Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55445 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
LICENSE AGREEMENTLicense Agreement • May 15th, 2014 • Arno Therapeutics, Inc • Pharmaceutical preparations • Delaware
This agreement (“License Agreement”) is entered into by and between Leica Biosystems Newcastle Ltd. (“LBS”) and Arno Therapeutics Inc. (“ARNO”), and is effective as of 23rd December 2013 (“Effective Date”).
MASTER DEVELOPMENT AND COMMERCIALIZATION AGREEMENTProject Agreement • May 15th, 2014 • Arno Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS MASTER DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of 23rd December, 2013 (the “Effective Date”), by and between Arno Therapeutics, Inc., having a place of business at 200 Route 31 North, Suite 104, Flemington, NJ 08822 (“ARNO”), and Leica Biosystems Newcastle Ltd., having a place of business at Balliol Business Park West, Benton Lane, Newcastle upon Tyne, United Kingdom NE12 8EW (“LBS”).
